Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Idec Senior VP International Business on Expanding Opportunities And Lessons Learned In Asia

This article was originally published in PharmAsia News

Executive Summary

Biogen Idec's strategy in emerging markets is not likely to change under the company's new CEO George Scangos, according to Senior VP International Business Gunther Winkler

You may also be interested in...

"With A Molecule That Is A Million Times Larger Than A Small Molecule, So Many Things Can Go Wrong," Says Biogen Idec Asia Operations Head Gunther Winkler

Gunther Winkler, Biogen Idec's Senior Vice President, International Business, is responsible for expanding the company's Asia operations. Winkler, a close watcher of biosimilars regulations being adapted by various countries, is skeptical about the safety of copied biotech drugs and therefore calls for sufficient caution on the approval mechanism for such drugs. In an interview with PharmAsia News' India bureau, Gunther Winkler spells out the company's ambitions in Asia, which includes research on products that could be relevant to local populations.

Biogen Set For Avonex Launch In India, But Concerned About Biosimilars Regulations

MUMBAI - Big Pharma has been increasingly attracted to the Indian market, but now big biotechs like Biogen Idec are also expanding their presence to make the most of the growth opportunities

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts